Trials / Completed
CompletedNCT00141154
Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan
A Randomized, Multicenter, Active And Placebo Controlled Parallel Group Study To Evaluate The Efficacy And Safety Of Celecoxib (Ym177) 200 Bid Compared To Loxoprofen 60 Mg Tid In Patients With Low Back Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,234 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To verify the superiority of celecoxib (YM177) 200 mg bid to placebo in treatment of patients with low back pain as well as non-inferiority to loxoprofen sodium 60 mg tid.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celecoxib | |
| DRUG | Placebo | |
| DRUG | Loxoprofen |
Timeline
- Start date
- 2004-10-01
- First posted
- 2005-09-01
- Last updated
- 2021-03-03
Locations
38 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00141154. Inclusion in this directory is not an endorsement.